Author

John Laterra

Kennedy Krieger Institute & Johns Hopkins School of Medicine - Cited by 16,279 - neuro-oncology

Biography

Dr. John J. Laterra is a research scientist at Kennedy Krieger Institute. He is also a professor in the Department of Neurology, Neuroscience and Oncology at Johns Hopkins University School of Medicine and Kennedy Krieger Institute. He is the director of the Division of Neuro-Oncology in the Department of Neurology at Johns Hopkins.
Title
Cited by
Year
Review and consensus recommendations on clinical APT‐weighted imaging approaches at 3T: application to brain tumors
J Zhou, M Zaiss, L Knutsson, PZ Sun, SS Ahn, S Aime, P Bachert, ...Magnetic resonance in medicine 88 (2), 546-574, 2022202
51
2022
d‐glucose weighted chemical exchange saturation transfer (glucoCEST)‐based dynamic glucose enhanced (DGE) MRI at 3T: early experience in healthy …
X Xu, AA Sehgal, NN Yadav, J Laterra, L Blair, J Blakeley, A Seidemo, ...Magnetic resonance in medicine 84 (1), 247-262, 2020202
42
2020
A Sox2: miR-486-5p axis regulates survival of GBM cells by inhibiting tumor suppressor networks
H Lopez-Bertoni, IS Kotchetkov, N Mihelson, B Lal, Y Rui, H Ames, ...Cancer research 80 (8), 1644-1655, 2020202
40
2020
Reprogramming transcription factors Oct4 and Sox2 Induce a BRD-dependent immunosuppressive transcriptome in GBM-propagating cells
T Ma, C Hu, B Lal, W Zhou, Y Ma, M Ying, P Prinos, A Quiñones-Hinojosa, ...Cancer research 81 (9), 2457-2469, 2021202
22
2021
Sox2 induces glioblastoma cell stemness and tumor propagation by repressing TET2 and deregulating 5hmC and 5mC DNA modifications
H Lopez-Bertoni, A Johnson, Y Rui, B Lal, S Sall, M Malloy, JB Coulter, ...Signal transduction and targeted therapy 7 (1), 37, 222
20
2022
ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma
C Hu, K Wang, C Damon, Y Fu, T Ma, L Kratz, B Lal, M Ying, S Xia, ...Neuro-oncology 24 (6), 888-900, 2022202
16
2022
Hemophagocytic lymphohistiocytosis secondary to PD-1 and IDO inhibition in a patient with refractory glioblastoma
R Thummalapalli, T Heumann, J Stein, S Khan, DS Priemer, AS Duffield, ...Case Reports in Oncology 13 (2), 508-514, 2020202
16
2020
Mutant IDH1 promotes phagocytic function of microglia/macrophages in gliomas by downregulating ICAM1
D Ma, D Zhan, Y Fu, S Wei, B Lal, J Wang, Y Li, H Lopez-Bertoni, F Yalcin, ...Cancer letters 517, 35-45, 2021202
13
2021
EGFR activates a TAZ-driven oncogenic program in glioblastoma
M Gao, Y Fu, W Zhou, G Gui, B Lal, Y Li, S Xia, H Ji, CG Eberhart, ...Cancer research 81 (13), 3580-352, 2021202
9
2021
ShRNA-based POLD2 expression knockdown sensitizes glioblastoma to DNA-damaging therapeutics
Q Xu, C Hu, Y Zhu, K Wang, B Lal, L Li, J Tang, S Wei, G Huang, S Xia, ...Cancer letters 482, 126-135, 2020202
7
2020
Exploring glioblastoma stem cell heterogeneity: Immune microenvironment modulation and therapeutic opportunities
AL Johnson, J Laterra, H Lopez-BertoniFrontiers in Oncology 12, 99498, 2022202
5
2022
Very long-chain acyl-CoA synthetase 3 mediates onco-sphingolipid metabolism in malignant glioma
EA Kolar, X Shi, EM Clay, AB Moser, B Lal, RS Nirujogi, A Pandey, ...Medical research archives 9 (5), 2021202
4
2021
Molecular clarification of brainstem astroblastoma with EWSR1-BEND2 fusion in a 38-year-old man
MA Smith-Cohn, Z Abdullaev, KD Aldape, M Quezado, MK Rosenblum, ...Free Neuropathology 2, 2021202
4
2021
Opinion: miRNAs–The new wave of molecular cancer therapeutics
H Lopez-Bertoni, J LaterraTranslational Oncology 14 (6), 101064, 2021202
3
2021
Targeting UDP-α-d-glucose 6-dehydrogenase alters the CNS tumor immune microenvironment and inhibits glioblastoma growth
D Zhan, F Yalcin, D Ma, Y Fu, S Wei, B Lal, Y Li, O Dzaye, J Laterra, ...Genes & Diseases 9 (), 717-70, 2022202
3
2022
Stem-03. Oct4/Sox2 drive an immunosuppressive gsc phenotype by inducing T-reg effector genes Via Tgfbr2 signaling
Stem-03. Oct4/Sox drive an immunosuppressive gsc phenotype by inducing T-reg effector genes Via Tgfbr signalingA Johnson, J Korleski, J Laterra, H Lopez-BertoniNeuro-Oncology 3 (Supplement_6), vi1-vi, 010
2
2021
Measuring cancer hallmark mediation of the TET1 glioma survival effect with linked neural-network based mediation experiments
T Luechtefeld, N Lin, C Paller, K Kuhns, JJ Laterra, JP BresslerScientific reports 10 (1), 8886, 000
2
2020
Monoallelic IDH1 R132H mutation mediates glioma cell response to anticancer therapies via induction of senescence
Monoallelic IDH R32H mutation mediates glioma cell response to anticancer therapies via induction of senescenceD Zhan, D Ma, S Wei, B Lal, Y Fu, C Eberhart, J Laterra, M Ying, Y Li, ...Molecular Cancer Research 9 (), 878-888, 20220
1
2021
Vitamin C enhances H3K36me3 via NSD1 promoter demethylation and sensitizes GBM stem cells to DNA damaging agents
Vitamin C enhances H3K36me3 via NSD promoter demethylation and sensitizes GBM stem cells to DNA damaging agentsH Khela, S Sudhir, M Fagundo-Lugo, B Lal, J Laterra, H Lopez-BertoniCancer Research 8 (3_Supplement), 224-224, 20220
1
2021
Impact of frontline ivosidenib on volumetric growth patterns in isocitrate dehydrogenase (IDH) mutant astrocytic and oligodendroglial tumors
DO Kamson, S Puri, Y Sang, MJ Shi, L Blair, JO Blakeley, J LaterraClinical Cancer Research, 2023202
1
2023

Referred From: https://scholar.google.com/citations?user=ToWm9jsAAAAJ&hl=en

Cited by
Citations 16279
h-index 71
i10-index 175
Recommended Journals
Open Access Journals